JIANMIN GROUP(600976) 国海证券·2025-04-21 07:32Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's main business profits have shown a strong recovery in Q1 2025, with a non-recurring net profit of 1.03 billion yuan, representing a year-on-year increase of 13.92%. The main business profit reached 640 million yuan, up 116% year-on-year [6] - The report highlights the positive impact of the company's marketing system reform initiated in 2024, which is expected to enhance short-term profit recovery and long-term revenue growth and profitability [6] - The demand for cultured gallstones is expected to grow steadily due to an aging population and the shortage of natural gallstones, providing significant replacement opportunities [6] Summary by Sections Financial Performance - In Q1 2025, the company achieved an operating income of 892 million yuan, down 8.04% year-on-year, while the net profit attributable to shareholders was 110 million yuan, up 10.70% year-on-year [4][6] - The report forecasts revenues for 2025-2027 to be 39.50 billion yuan, 43.45 billion yuan, and 47.80 billion yuan, respectively, with net profits of 5.46 billion yuan, 6.25 billion yuan, and 7.41 billion yuan [6][8] Market Position and Growth Drivers - The company is expected to maintain high growth in its OTC and hospital sales channels, with significant market share increases for products like "Bengtong Capsule" and "Jianpi Shengxue Granule" [6] - New product launches, including pediatric and prescription drugs, are anticipated to contribute to sustained growth in the prescription line [6] Long-term Outlook - The report emphasizes the long-term growth potential of cultured gallstones, driven by increasing health demands and the aging population, which is expected to benefit downstream products containing gallstones [6]